Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2011.1.1-1 | Award Amount: 7.80M | Year: 2011
Glycosylation is a post-translational modification that enriches protein complexity and function. Dysregulation of glycosylation is associated with a wide range of diseases, including cancer, diabetes, as well as congenital, cardiovascular, immunological and infectious disorders. A number of studies identified potentially important glycan disease biomarkers. With regard to biotechnology, proper glycosylation of biologicals is important, as deviations in glycosylation are known to be associated with adverse drug reactions and reduced therapeutic efficacy. However, glycomics is significantly lagging behind genomics and proteomics, mainly due to the absence of high-throughput analytical methods which can reliably quantify a multitude of glycan structures in complex biological samples. We are confident that by coordinated efforts of leading European scientists in glycan analysis using HPLC, MS and CGE-LIF technologies this project will make a decisive step forward by developing real high-throughput tools for glycosylation analysis. By teaming up with leading European researchers in the field of genome wide association studies this project will perform validation of all methods on extremely well characterized set of samples resulting from the FP6 EuroSpan project. The addition of the newly generated glycome data to the pre-existing information about these individuals will enable development of methods for the systems biology approach analysis of the glycome which will integrate glycomic, genomic and environmental data about thousands of individuals. The same methods will also be adapted for quality control and monitoring in the production of biopharmaceuticals. Strong participation of SMEs in the project and close contacts with large industrial partners will ensure that research accomplishments achieved by collaboration between academic and industrial scientists are swiftly transformed into innovative products and services for the benefit of European industry.
Glyxera Gmbh | Date: 2013-01-15
Measuring, signaling, and checking apparatus and instruments, namely, clinical laboratory analyzers for measuring, testing, and analyzing blood and other bodily fluids, lasers for measuring purposes, electric sensors; data processing equipment, namely, data processors; computers; computer software, namely, for use in database management; computer programs, namely, for use in database management; data processing programs and apparatus and instruments with said data processing programs, namely, data processors sold together with computer software for processing data and providing a statistical analysis of data; all goods in particular in the field of the analytics of carbohydrates. Education and training, in particular education in the nature of classes, seminars, and workshops on technical and scientific services in the field of analytics of carbohydrates; arranging and conducting conferences, congresses and symposiums in the field of the analytics of carbohydrates; arranging and conduction of training workshops in the field of the analytics of carbohydrates. Scientific and technological services and research and design relating thereto, namely, scientific research, analysis, and testing in the field of the analytics of carbohydrates; industrial scientific analysis and research services in the field of the analytics of carbohydrates, design and development of computer hardware and software in the field of the analytics of carbohydrates.